AR and prostate cancer: To determine the extent to which proteomic responses to androgens and antiandrogens overlap in the presence of this mutant receptor, we exposed the LNCaP prostate cancer cell line, which harbors the T877A AR variant, to the dihydrotestosterone (DHT) analog mibolerone, cyproterone acetate, hydroxyflutamide, and bicalutamide.